CN112007170A - Immunologic adjuvant functionalized metal organic framework material and preparation method and application thereof - Google Patents
Immunologic adjuvant functionalized metal organic framework material and preparation method and application thereof Download PDFInfo
- Publication number
- CN112007170A CN112007170A CN202010821248.XA CN202010821248A CN112007170A CN 112007170 A CN112007170 A CN 112007170A CN 202010821248 A CN202010821248 A CN 202010821248A CN 112007170 A CN112007170 A CN 112007170A
- Authority
- CN
- China
- Prior art keywords
- mof
- icg
- cpg
- metal organic
- organic framework
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 70
- 239000000568 immunological adjuvant Substances 0.000 title claims abstract description 19
- 239000013183 functionalized metal-organic framework Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000012621 metal-organic framework Substances 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 230000001571 immunoadjuvant effect Effects 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 6
- 238000007626 photothermal therapy Methods 0.000 claims abstract description 5
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 32
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 claims description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 229960004657 indocyanine green Drugs 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 14
- 238000011068 loading method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 239000003504 photosensitizing agent Substances 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- GPNNOCMCNFXRAO-UHFFFAOYSA-N 2-aminoterephthalic acid Chemical compound NC1=CC(C(O)=O)=CC=C1C(O)=O GPNNOCMCNFXRAO-UHFFFAOYSA-N 0.000 claims description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 5
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000000527 sonication Methods 0.000 claims description 5
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 5
- 239000012498 ultrapure water Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- -1 iron carboxylate Chemical class 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 33
- 238000003384 imaging method Methods 0.000 abstract description 16
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 210000000987 immune system Anatomy 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 238000001126 phototherapy Methods 0.000 abstract description 4
- 238000005481 NMR spectroscopy Methods 0.000 abstract description 3
- 238000000862 absorption spectrum Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 239000002086 nanomaterial Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
- 238000000799 fluorescence microscopy Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000013532 laser treatment Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 231100000683 possible toxicity Toxicity 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000034701 macropinocytosis Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Acoustics & Sound (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an immunoadjuvant functionalized metal organic framework material, and a preparation method and application thereof, wherein the preparation process comprises the step of synthesizing MIL-101-NH2Namely MOF, ICG and MOF are combined into MOF-ICG, and MOF-ICG is loaded with CpG; the material can be applied to the preparation of medicines. Advantages of the invention include (1) UV-VISIBILITY of the materials provided by the inventionThe absorption spectrum peak value is positioned around near infrared light, the near infrared laser with single wavelength can be used for exciting the photodynamic and photothermal effect at the same time, and the nano-structure has excellent singlet oxygen generation capacity and photothermal conversion capacity under the irradiation of the near infrared laser, and has great application potential in the aspect of tumor phototherapy. (2) In a tumor microenvironment, CpG loaded by the material and TAA released by photodynamic and photothermal therapy jointly activate an immune system, enhance tumor cytotoxicity and improve treatment effect. (3) The material provided by the invention has the functions of tumor multi-modal imaging (fluorescence, photoacoustic, photothermal and nuclear magnetic resonance), and can be used for monitoring the tumor position and the treatment effect.
Description
Technical Field
The invention relates to the technical field of photodynamic and photothermal treatment carriers, in particular to preparation and application of an immunologic adjuvant functionalized material.
Background
Photodynamic and photothermal therapy is receiving increasing attention in the field of tumor therapy as a promising treatment. In recent years, various nano-carrier systems greatly improve the bioavailability and tumor enrichment rate of photosensitive molecules, but still have problems such as potential toxicity, low photosensitive drug loading efficiency, high early release rate and the like. The reason is that the introduced carrier material has long degradation period and even can not be degraded, the loading of the photosensitive drug is limited to non-covalent interaction, and no covalent interaction force is introduced, so that the stability of the carrier system is greatly reduced. The metal organic framework material with good biocompatibility and degradability is used for loading the photosensitizer, and the photosensitizer and the metal organic framework material are covalently combined, so that the loading efficiency and potential toxicity of the photosensitizer can be effectively improved. In addition, in order to improve the immune response rate, the introduction of the immune adjuvant can effectively stimulate the immune system and improve the treatment effect.
The metal organic framework material is taken as a research object, a photosensitizer and an immunologic adjuvant are loaded, a novel nano drug-carrying system is developed, multi-modal imaging and high-efficiency photodynamic and photothermal treatment modes of tumors are realized, and the method has a wide prospect of loading the immunologic adjuvant to improve the response rate of the tumors.
Disclosure of Invention
The object of the present invention is to provideCovalent loading photosensitizer indocyanine green (ICG) and porous electrostatic adsorption immunological adjuvant cytosine guanine dinucleotide (CpG) nano iron carboxylate metal organic framework (MIL-101-NH)2) The material (ICG-CpG @ MOF) can be passively targeted to a tumor part through an EPR effect, so that tumor multi-mode imaging (fluorescence, optoacoustic, photothermal and nuclear magnetic resonance) is realized, two treatment modes of photodynamic and photothermal can be realized simultaneously, the CpG and a tumor antigen (TAA) released by treatment can effectively activate an immune system, and the killing effect of tumor cells is enhanced.
Another object of the present invention is to provide a process for the preparation of the ICG-CpG @ MOF material described above;
in order to achieve the purpose, the invention adopts the following technical scheme:
the ICG-CpG @ MOF material takes a nano iron carboxylate metal organic framework (MIL-101-NH2) as a core, and is covalently connected with a photosensitizer ICG and a porous electrostatic adsorption immunoadjuvant CpG. The preparation process comprises the following steps: synthesis of MIL-101-NH2Namely MOF, ICG and MOF are combined to form MOF-ICG, and the MOF-ICG is loaded with CpG.
Further, the process of synthesizing MOFs comprises:
(1) separately dissolving 2-aminoterephthalic acid and FeCl3·6H2O；
(2) Adding the two liquids obtained in the step (1) into a high-pressure kettle for high-temperature mixing treatment;
(3) centrifuging the liquid obtained in the step (2), and removing the supernatant to collect precipitate to obtain precipitated powder;
(4) washing the precipitated starch powder;
(5) and drying the washed powder to obtain the product MOF.
Further, the detailed process of synthesizing MOFs is:
(1) 375mg of 2-aminoterephthalic acid and 1125mg of FeCl3·6H2O is dissolved in 12.5ml of dimethylformamide respectively;
(2) putting the two liquids in the step (1) into a 50ml stainless steel autoclave, and treating the mixture at 120 ℃ for 24 hours;
(3) centrifuging the liquid obtained in the step (2) at 8000rpm for 10 minutes, discarding the supernatant, and collecting the precipitate to obtain precipitated powder;
(4) washing the precipitated powder in the step (3) with dimethylformamide and ethanol for 3 times in sequence;
(5) vacuum drying the washed powder of (4) at 50 deg.C for 8 hr to obtain MIL-101-NH2(MOF)。
Further, the process of the ICG binding to MOF-ICG is:
(1) activating carboxyl of ICG-COOH;
(2) adding MOF into the mixture obtained in the step (1), and stirring;
(3) and (3) centrifuging the liquid in the step (2), discarding the supernatant, and recovering the precipitate to obtain the MOF-ICG combined product of ICG and MOF.
Further, the detailed process of the ICG binding to MOF-ICG is:
(1) 100mM, 10. mu.L EDC and 100mM, 10. mu.L NHS were added to 10mM, 200. mu.L ICG-COOH solution and the mixture was sonicated for 30 minutes to ensure thorough mixing, the purpose of this step being to activate the carboxyl groups;
(2) adding 10mg/mL,1mL MOF to the mixture of (1), and stirring at room temperature for 24 hours;
(3) centrifuging the liquid obtained in the step (2) at 8500 rpm for 10 minutes, discarding the supernatant, and recovering the precipitate to obtain a product of ICG and MOF combination, namely MOF-ICG.
Further, the MOF-ICG CpG-loading process is as follows:
(1) adding MOF-ICG to ultrapure water and suspending it using sonication;
(2) dissolving CpG in the solution in the step (1), and stirring at room temperature for 0.5 hour;
(3) and (3) centrifuging the solution obtained in the step (2), discarding the supernatant, and recovering and precipitating to obtain the CpG-loaded MOF-ICG which is expressed as ICG-CpG @ MOF.
Further, the detailed process of MOF-ICG CpG loading is as follows:
(1) 1.2mg of MOF-ICG was added to 1ml of ultrapure water and suspended using sonication;
(2) dissolving 84. mu.g of CpG in the solution of (1), and stirring at room temperature for 0.5 hour;
(3) the solution obtained in (2) was centrifuged at 8500 rpm for 10 minutes, the supernatant was discarded, and the MOF-ICG precipitated as a CpG-loaded fragment was recovered as ICG-CpG @ MOF.
The third object of the present invention is to provide the use of the ICG-CpG @ MOF material described above for the preparation of a medicament, in particular for the preparation of a medicament for photodynamic and photothermal therapy.
The light immunotherapy principle of the invention is as follows: in tumor phototherapy, the ICG-CpG @ MOF material enters tumor cells through macropinocytosis, the loaded ICG can absorb near infrared light and convert the near infrared light into heat energy, and a photosensitizer can be excited in the early stage of illumination under illumination to play a photodynamic treatment effect; with the extension of the illumination time, the photothermal effect of the ICG plays a role, and the synergistic phototherapeutic is realized. Photodynamic and photothermal therapeutic effects can destroy tumor cells, resulting in the release of tumor cell antigens (TAAs). The released TAA and CpG loaded by the material activate an immune system together, so that the effect of killing tumor cells is obviously enhanced, and the treatment effect is improved.
Has the advantages that: (1) the ultraviolet-visible absorption spectrum peak value of the material provided by the invention is positioned around near infrared light, the near infrared laser with single wavelength can be used for simultaneously exciting the photodynamic and photothermal effects, and the material has excellent singlet oxygen generation capacity and photothermal conversion capacity under the irradiation of the near infrared laser, and has huge application potential in the aspect of tumor phototherapy. (2) In a tumor microenvironment, CpG loaded by the material and TAA released by photodynamic and photothermal therapy jointly activate an immune system, enhance tumor cytotoxicity and improve treatment effect. (3) The material provided by the invention has the functions of tumor multi-modal imaging (fluorescence, photoacoustic, photothermal and nuclear magnetic resonance), and can be used for monitoring the tumor position and the treatment effect.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the invention and together with the description serve to explain the principles of the invention:
FIG. 1 is a schematic representation of the technical scheme for ICG-CpG @ MOF materials and their use.
FIG. 2 is a schematic diagram of the synthesis and application of ICG-CpG @ MOF material. A schematic synthesis of icg-CpG @ MOF; B. the multi-modal imaging (photoacoustic, nuclear magnetism and fluorescence imaging) guides a mechanism of the synergetic tumor photoimmunotherapy, ICG-CpG @ MOF is enriched in tumor tissues through an EPR effect, and 808nm laser activates photoimmunotherapy.
FIG. 3 is a graph showing the results of the characterization of ICG-CpG @ MOF material. A. Observing the morphology of the MOF by using a transmission electron microscope; B. observing the morphology of the MOF by a scanning electron microscope; particle size before and after mof modification; a bright field TEM image and an element mapping spectrum in STEM mode of ICG-CpG @ MOF; fourier transform infrared spectroscopy (FT-IR) of icg @ MOF; zeta potential before and after mof modification; ultraviolet absorption spectra of icg @ MOF and MOF alone.
FIG. 4 time-dependent internalization of FAM-ICG-CpG @ MOF by tumor cells. A. Imaging tumor cell internalization ICG-CpG @ MOF using confocal microscopy; B. flow cytometry examined the internalization efficiency of ICG-CpG @ MOF.
FIG. 5 photo-thermal and photodynamic effects of ICG-CpG @ MOF. Temperature imaging of icg-CpG @ MOF at different power densities (under 808nm laser illumination); increased temperature in an aqueous icg-CpG @ MOF solution (1mL) at different power densities by a 808nm laser; photothermal conversion stability of icg-CpG @ MOF (100 ° f g/mL); D. fluorescence microscopy detected ROS levels, (-) indicated no laser treatment and (+) indicated laser treatment; E. flow cytometry detection of ROS levels (-) indicates no laser treatment, (+) indicates laser treatment; F. detecting the effect of ICG-CpG @ MOF on apoptosis by flow cytometry; G. the effect of ICG-CpG @ MOF on apoptosis was examined by fluorescence microscopy.
FIG. 6. effect of ICG-CpG @ MOF on immune cell differentiation. The regulation and control effect of MOF on peritoneal macrophages; B. peritoneal macrophage CD80 expression analysis; the regulation and control effect of ICG-CpG @ MOF on spleen adherent cells; D. splenic adherent cell CD80 expression assay; E. effect of photothermal treatment on expression of splenic T cells CD4 and CD 8.
FIG. 7 multimodal imaging functionality of ICG-CpG @ MOF. A. Tumor near-infrared fluorescence in-situ imaging after tail vein injection; B. tumor in-situ near-infrared fluorescence imaging is carried out 24 hours after tail vein injection; C. the distribution of ICG-CpG @ MOF in each organ after 6h of tail vein injection; D. in-situ photothermal imaging; nuclear magnetic horizontal section (E) and coronal section (F) of tumor-bearing mice; G. photoacoustic imaging of tumors before and after in situ injection; H. PA images of ICG-CpG @ MOF solutions at different concentrations in vitro (0, 0.5, 1, 2, 5, and 10. mu.g/mL, respectively).
FIG. 8 in vivo therapeutic effect of ICG-CpG @ MOF. A. Tumor volume changes before and after treatment; B. statistical analysis of tumor volume; C. the therapeutic effect of lung metastasis; D. tumor and organ H & E staining before and after treatment in tumor-bearing mice.
Detailed Description
The present invention will be described in detail with reference to the drawings and specific embodiments, which are illustrative of the present invention and are not to be construed as limiting the present invention.
FIG. 1 is a schematic diagram of an ICG-CpG @ MOF material and a technical scheme for its use, the details of which are illustrated by the following specific examples.
Example Synthesis of ICG-CpG @ MOF Material
The synthetic ICG-CpG @ MOF material mainly comprises 3 parts: synthesis of MIL-101-NH2(MOF), ICG and MOF are combined into MOF-ICG, and the MOF-ICG is loaded with CpG.
MIL-101-NH2The (MOF) synthesis procedure was as follows:
(1) 375mg of 2-aminoterephthalic acid and 1125mg of FeCl3·6H2O is dissolved in 12.5ml of dimethylformamide respectively;
(2) putting the two liquids in the step (1) into a 50ml stainless steel autoclave, and treating the mixture at 120 ℃ for 24 hours;
(3) centrifuging the liquid obtained in the step (2) at 8000rpm for 10 minutes, discarding the supernatant, and collecting the precipitate to obtain precipitated powder;
(4) washing the precipitated powder in the step (3) with dimethylformamide and ethanol for 3 times in sequence;
(5) vacuum drying the washed powder of (4) at 50 deg.C for 8 hr to obtain MIL-101-NH2(MOF)。
ICG binding to MOF:
(6) EDC (100mM, 10. mu.L) and NHS (100mM, 10. mu.L) were added to the ICG-COOH (10mM, 200. mu.L) solution and the mixture was sonicated for 30 minutes to ensure adequate mixing, the purpose of this step being to activate the carboxyl groups;
(7) adding the MOF obtained in (5) (10mg/mL,1mL) to the mixture in (6), and stirring at room temperature for 24 hours;
(8) centrifuging the liquid obtained in the step (7) at 8500 rpm for 10 minutes, discarding the supernatant, and recovering the precipitate to obtain an ICG and MOF combined product (MOF-ICG).
MOF-ICG Loading CpG:
(9) 1.2mg of MOF-ICG was added to 1ml of ultrapure water and suspended using sonication;
(10) CpG (84. mu.g) was dissolved in the solution described in (9) and stirred at room temperature for 0.5 hours;
(11) the solution obtained in (10) was centrifuged at 8500 rpm for 10 minutes, the supernatant was discarded, and the precipitate was recovered as CpG-loaded MOF-ICG (denoted as ICG-CpG @ MOF). The synthetic schematic diagram is shown in FIG. 2A; the technical route of application of ICG-CpG @ MOF is shown in figure 1, and the principle of photo-immunotherapy is shown in figure 2B; the characterization results of the synthesized materials are shown in fig. 3. The results of experiments relating to time-dependent internalization of FAM-ICG-CpG @ MOF by tumor cells are shown in FIG. 4.
Example two photodynamic and photothermal effects of ICG-CpG @ MOF materials
(1) Dissolving the ICG-CpG @ MOF material in deionized water to ensure that the concentration of the ICG-CpG @ MOF material in a system is 100 mug/mL; placing the solution at 0.5, 1.0, 1.5, 2W/cm2Irradiating for 0-5 minutes under near infrared laser with wavelength of 808nm, and recording temperature change; as shown in FIG. 5, the temperature of the material gradually rises within 5min, and after 5min, the temperature reaches a stable level and is maintained at a higher level, which proves that the material has better photothermal conversion capability. Furthermore, as shown in FIG. 5C, ICG-CpG @ MOF can replicate well in response to photothermal conversion induced by a 808nm laser (1.5W/cm 2). The latter experiment was irradiated with a 808nm laser (1.5W/cm2) for 5 min.
(2) To examine the photodynamic effect of the material, ICG-CpG @ MOF material (final concentration 20nM, the same final concentration for the following cell assay) was incubated with 4T1 tumor cells, as shown in fig. 4, over a period of time, the proportion of material entering the cells increased with time, the cells were then incubated with a commercially available active oxygen probe (DCFH-DA), and the cell system was exposed to 1.5W/cm2 of near infrared laser at 808nM wavelength to measure the intensity of the fluorescence signal from the solution; as shown in FIG. 5D, the laser-irradiated group alone slightly increased intracellular ROS levels, and the fluorescence intensity of the ICG-CpG @ MOF + laser group was significantly increased. Flow cytometry to detect ROS levels as in fig. 5 e; the effect of ICG-CpG @ MOF on apoptosis was examined by fluorescence microscopy as shown in figure 5g. It can be seen that the ROS level of the cells is increased and the apoptosis rate is obviously increased after the laser treatment of ICG-CpG @ MOF +.
Example killing of 4T1 tumor cells by the TriICG-CpG @ MOF Material
Inoculating 4T1 cells in logarithmic growth phase to a 6-hole culture plate, culturing overnight, and after the cells are completely attached to the wall, discarding the old culture medium, wherein the method comprises the following steps: and after corresponding grouping treatment is carried out on a control group, a single ICG-CpG @ MOF group, a single laser group and an ICG-CpG @ MOF + laser group, the apoptosis condition is detected by using a commercially available apoptosis detection kit. The result is shown in fig. 5F, and it can be seen from the figure that the tumor cells of the single ICG-CpG @ MOF group and the single laser group have no significant change compared with the control group, and the apoptosis rate of the ICG-CpG @ MOF + laser group is significantly increased, which proves that the material has a better effect of promoting the apoptosis of the tumor cells in the phototherapy process.
Example four ICG-CpG @ MOF Material activation of immune cells
(1) Separating primary abdominal cavity macrophages of a mouse, setting a blank control group control, respectively co-culturing CpG, MOF and ICG-CpG @ MOF materials and the separated macrophages for 48 hours, and detecting the expression of CD80 and CD11c by flow cytometry. The results are shown in FIGS. 6A-B, and it can be seen from the figure that CpG and ICG-CpG @ MOF material can promote the expression of macrophages CD80 and CD11c, i.e. CpG and ICG-CpG @ MOF material has stronger activation effect on macrophages.
(2) Mouse spleen cells are separated, and after 4T1 cells, CpG, MOF, ICG-CpG @ MOF material and laser are respectively cocultured with spleen adherent cells or suspended T cells for 48 hours, the expression of CD80 and CD11c of the mouse spleen cells is detected by flow cytometry. As shown in FIGS. 6C and D, CpG promotes the expression of spleen adherent CD80 and CD11C, while 4T1 inhibits the expression of spleen adherent CD80 and CD 11C. As shown in FIG. 6E, the expression of T cell CD8 was significantly enhanced after the co-culture of ICG-CpG @ MOF and the residues after the laser treatment of the cells and the suspension T cells separated from the spleen, indicating that the ICG-CpG @ MOF material designed by the present invention has a good immune activation effect.
In addition, experiments relating to the effect of ICG-CpG @ MOF immunotherapy were also performed and the results are shown in FIG. 7.
EXAMPLE therapeutic Effect of the five ICG-CpG @ MOF materials on tumor-bearing mice
(1) Bal B/C mice (4-6 weeks) were used as experimental animals and inoculated with 1 x 1064T1 cells were used to construct a subcutaneous tumor model, which was randomized into 3 groups when the tumor diameter was approximately 8 mm: PBS group, ICG-CpG @ MOF group and ICG-CpG @ MOF + laser group, the dosage of ICG-CpG @ MOF is 25mg/kg, the same dosage is used in the following animal experiments, and the tumor size of each group is observed. The results are shown in fig. 8A and B, the ICG-CpG @ MOF + laser group forms target tumor lesions on the 7 th day, the tumor lesions basically disappear on the 21 th day, and the experimental results show that the ICG-CpG @ MOF material designed by the invention has good tumor killing effect compared with other groups.
(2) Bal B/C mice (4-6 weeks) as experimental animals, 1 x 1064T1 cells were injected into the mouse tail vein in order to model 4T1 metastases. Mice were randomized into 3 groups: PBS control group, ICG-CpG @ MOF group and ICG-CpG @ MOF + LASER group. The results are shown in FIG. 8C, and 21 days after tumor cell injection, the tumor cells of PBS control group infiltrated the whole lung of the mouse, while the tumor of ICG-CpG @ MOF + laser group was significantly inhibited. In order to detect the histocompatibility of the material and the influence on each organ, each group of tumor-bearing mouse tissues is subjected to H&And E, dyeing. The results are shown in FIG. 8D, in which ICG-CpG @ MOF + laser group tumor cells exhibited vacuolization, H, compared to the PBS control group&E No obvious lesion was observed in each organ stained. The ICG-CpG @ MOF material designed by the invention has a good metastatic tumor killing effect, has no obvious damage to each organ, and has good biocompatibility.
Example six ICG-CpG @ MOF Material Multi-modality imaging functionality
(1) Bal B/C mice (4-6 weeks) were used as experimental animals and inoculated with 1 x 1064T1 cells were used to construct a subcutaneous tumor model, and the effect of fluorescence imaging of the material was evaluated after tail vein injection of ICG-CpG @ MOF when the tumor diameter was about 8 mm. As a result, as shown in FIG. 7A, fluorescence was detected at the tumor site 1 hour after the injection of the materialSignal, and the signal gradually increased over 6 hours. The distribution of ICG-CpG @ MOF in each organ 6h after tail vein injection is shown in FIG. 7C; the fluorescence intensity 24 hours after the injection of the material was analyzed by using a multifunctional near-infrared scanner (to avoid the fluorescence interference of the organ site), and the results are shown in fig. 7B, and the tumor site still detected strong fluorescence signals at 24 hours, indicating that the ICG-CpG @ MOF material has a good fluorescence imaging function.
(2) Bal B/C mice (4-6 weeks) were used as experimental animals and inoculated with 1 x 1064T1 cells were used to construct a subcutaneous tumor model, which was randomized into 3 groups when the tumor diameter was approximately 8 mm: the system comprises a laser group, an ICG @ MOF group and an ICG @ MOF + laser group, wherein the photothermal imaging result is evaluated by an infrared thermal imager after the groups are processed. The results are shown in FIG. 7D, which shows good photothermographic results for the ICG @ MOF + laser group after material injection.
(3) Bal B/C mice (4-6 weeks) were used as experimental animals and inoculated with 1 x 1064T1 cells were used to construct a subcutaneous tumor model, which was randomized into 2 groups when the tumor diameter was approximately 8 mm: PBS control group, ICG-CpG @ MOF group, and the effect of MRI was evaluated after each group was treated. The results are shown in FIGS. 7E-F, and the ICG-CpG @ MOF material can significantly improve the nuclear magnetic imaging effect of the tumor site.
(4) Bal B/C mice (4-6 weeks) were used as experimental animals and inoculated with 1 x 1064T1 cells are used for constructing a subcutaneous tumor model, when the diameter of the tumor is about 8mm, photoacoustic signals of the tumor are detected before and 6 hours after the ICG-CpG @ MOF material is injected, and the photoacoustic imaging effect of the material is evaluated. The results are shown in FIGS. 7G-H, where there is a strong photoacoustic signal 6 hours after the material was injected, indicating that the ICG-CpG @ MOF material has good photoacoustic imaging function.
The technical solutions provided by the embodiments of the present invention are described in detail above, and the principles and embodiments of the present invention are explained herein by using specific examples, and the descriptions of the embodiments are only used to help understanding the principles of the embodiments of the present invention; meanwhile, for a person skilled in the art, according to the embodiments of the present invention, there may be variations in the specific implementation manners and application ranges, and in summary, the content of the present description should not be construed as a limitation to the present invention.
Claims (10)
1. An immunoadjuvant functionalized metal organic framework material is characterized in that the material is a nano iron carboxylate metal organic framework MIL-101-NH which is covalently loaded with photosensitizer indocyanine green ICG and immunoadjuvant cytosine guanine dinucleotide CpG adsorbed by porous static electricity2The material, denoted ICG-CpG @ MOF.
2. A method for preparing an immunoadjuvant functionalized metal organic framework material according to claim 1, wherein the method comprises the following steps:
the process comprises the following steps: synthesis of MIL-101-NH2Namely MOF, ICG and MOF are combined to form MOF-ICG, and the MOF-ICG is loaded with CpG.
3. The method for preparing an immunoadjuvant functionalized metal organic framework material according to claim 2, wherein the method comprises the following steps:
the process for synthesizing the MOF comprises the following steps:
(1) separately dissolving 2-aminoterephthalic acid and FeCl3·6H2O；
(2) Adding the two liquids obtained in the step (1) into a high-pressure kettle for high-temperature mixing treatment;
(3) centrifuging the liquid obtained in the step (2), and removing the supernatant to collect precipitate to obtain precipitated powder;
(4) washing the precipitated starch powder;
(5) and drying the washed powder to obtain the product MOF.
4. The method for preparing an immunoadjuvant functionalized metal organic framework material according to claim 3, wherein the method comprises the following steps:
the detailed process for the synthesis of MOFs is:
(1) 375mg of 2-aminoterephthalic acid and 1125mg of FeCl3·6H2O is dissolved in 12.5ml of dimethylformamide respectively;
(2) putting the two liquids in the step (1) into a 50ml stainless steel autoclave, and treating the mixture at 120 ℃ for 24 hours;
(3) centrifuging the liquid obtained in the step (2) at 8000rpm for 10 minutes, discarding the supernatant, and collecting the precipitate to obtain precipitated powder;
(4) washing the precipitated powder in the step (3) with dimethylformamide and ethanol for 3 times in sequence;
(5) vacuum drying the washed powder of (4) at 50 deg.C for 8 hr to obtain MIL-101-NH2(MOF)。
5. The method for preparing an immunoadjuvant functionalized metal organic framework material according to claim 2, wherein the method comprises the following steps:
the process of the ICG binding to MOF-ICG is:
(1) activating carboxyl of ICG-COOH;
(2) adding MOF into the mixture obtained in the step (1), and stirring;
(3) and (3) centrifuging the liquid in the step (2), discarding the supernatant, and recovering the precipitate to obtain the MOF-ICG combined product of ICG and MOF.
6. The method for preparing an immunoadjuvant functionalized metal organic framework material according to claim 5, wherein the method comprises the following steps:
the detailed process of the ICG binding to MOF-ICG is:
(1) 100mM, 10. mu.L EDC and 100mM, 10. mu.L NHS were added to 10mM, 200. mu.L ICG-COOH solution and the mixture was sonicated for 30 minutes to ensure thorough mixing, the purpose of this step being to activate the carboxyl groups;
(2) adding 10mg/mL,1mL MOF to the mixture of (1), and stirring at room temperature for 24 hours;
(3) centrifuging the liquid obtained in the step (2) at 8500 rpm for 10 minutes, discarding the supernatant, and recovering the precipitate as a product of the combination of ICG and MOF, namely MOF-ICG.
7. The method for preparing an immunoadjuvant functionalized metal organic framework material according to claim 2, wherein the method comprises the following steps:
the MOF-ICG CpG-loading process is as follows:
(1) adding MOF-ICG to ultrapure water and suspending it using sonication;
(2) dissolving CpG in the solution in the step (1), and stirring at room temperature for 0.5 hour;
(3) and (3) centrifuging the solution obtained in the step (2), discarding the supernatant, and recovering and precipitating to obtain the CpG-loaded MOF-ICG which is expressed as ICG-CpG @ MOF.
8. The method for preparing an immunoadjuvant functionalized metal organic framework material according to claim 7, wherein the method comprises the following steps:
the detailed process of MOF-ICG CpG loading is as follows:
(1) 1.2mg of MOF-ICG was added to 1ml of ultrapure water and suspended using sonication;
(2) dissolving 84. mu.g of CpG in the solution of (1), and stirring at room temperature for 0.5 hour;
(3) the solution obtained in (2) was centrifuged at 8500 rpm for 10 minutes, the supernatant was discarded, and the MOF-ICG precipitated as a CpG-loaded fragment was recovered as ICG-CpG @ MOF.
9. Use of an immunoadjuvant functionalized metal organic framework material according to claim 1 for the preparation of a medicament.
10. Use of an immunoadjuvant functionalized metal organic framework material according to claim 1 or 9 for the preparation of a medicament for photodynamic and photothermal therapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010821248.XA CN112007170B (en) | 2020-08-14 | 2020-08-14 | Immune adjuvant functionalized metal organic framework material and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010821248.XA CN112007170B (en) | 2020-08-14 | 2020-08-14 | Immune adjuvant functionalized metal organic framework material and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112007170A true CN112007170A (en) | 2020-12-01 |
| CN112007170B CN112007170B (en) | 2023-06-13 |
Family
ID=73504598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010821248.XA Active CN112007170B (en) | 2020-08-14 | 2020-08-14 | Immune adjuvant functionalized metal organic framework material and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112007170B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114259476A (en) * | 2021-12-29 | 2022-04-01 | 中南大学湘雅三医院 | Nanometer preparation for regulating and controlling macrophage, and preparation method and application thereof |
| CN115025248A (en) * | 2021-02-22 | 2022-09-09 | 西安电子科技大学 | Iron-based ICG metal organic nano composite (MONs) and preparation method and application thereof |
| CN115300641A (en) * | 2022-08-01 | 2022-11-08 | 深圳市人民医院 | Antigen delivery carrier for promoting antigen lysosome escape and activating immune system by targeting dendritic cells and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733744B1 (en) * | 2000-10-16 | 2004-05-11 | Mallinckrodt Inc. | Indole compounds as minimally invasive physiological function monitoring agents |
| CN108939072A (en) * | 2018-07-13 | 2018-12-07 | 湖北大学 | A kind of nano-carrier and preparation method thereof for photodynamic therapy |
| WO2019086542A1 (en) * | 2017-10-31 | 2019-05-09 | Cambridge Enterprise Limited | Metal organic framework-based compositions and uses thereof |
| CN110437239A (en) * | 2019-07-01 | 2019-11-12 | 山东师范大学 | Load the metal-organic framework material and preparation method and application of four-(N- methacrylic amine) phthalocyanine compounds |
| CN110522910A (en) * | 2019-08-01 | 2019-12-03 | 山东大学 | Based on metal organic frame administration nano-drug administration system and its preparation method and application |
| US20200000934A1 (en) * | 2017-02-28 | 2020-01-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Conjugates comprising ocular angiogenesis growth factor aptamers and uses thereof in the detection and treatment of ophthalmological angiogenesis indications |
| CN111194232A (en) * | 2017-08-02 | 2020-05-22 | 芝加哥大学 | Nanoscale metal-organic layers and metal-organic nanoplatelets for X-ray induced photodynamic therapy, radiotherapy, photodynamic therapy, chemotherapy, immunotherapy and any combination thereof |
| CN111467491A (en) * | 2020-04-24 | 2020-07-31 | 东南大学 | Synthesis of platinum modified MOF2-Pt-FA as bidirectional enhanced photodynamic therapy medicine and application of platinum modified MOF2-Pt-FA in tumor therapy |
-
2020
- 2020-08-14 CN CN202010821248.XA patent/CN112007170B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733744B1 (en) * | 2000-10-16 | 2004-05-11 | Mallinckrodt Inc. | Indole compounds as minimally invasive physiological function monitoring agents |
| US20200000934A1 (en) * | 2017-02-28 | 2020-01-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Conjugates comprising ocular angiogenesis growth factor aptamers and uses thereof in the detection and treatment of ophthalmological angiogenesis indications |
| CN111194232A (en) * | 2017-08-02 | 2020-05-22 | 芝加哥大学 | Nanoscale metal-organic layers and metal-organic nanoplatelets for X-ray induced photodynamic therapy, radiotherapy, photodynamic therapy, chemotherapy, immunotherapy and any combination thereof |
| WO2019086542A1 (en) * | 2017-10-31 | 2019-05-09 | Cambridge Enterprise Limited | Metal organic framework-based compositions and uses thereof |
| CN108939072A (en) * | 2018-07-13 | 2018-12-07 | 湖北大学 | A kind of nano-carrier and preparation method thereof for photodynamic therapy |
| CN110437239A (en) * | 2019-07-01 | 2019-11-12 | 山东师范大学 | Load the metal-organic framework material and preparation method and application of four-(N- methacrylic amine) phthalocyanine compounds |
| CN110522910A (en) * | 2019-08-01 | 2019-12-03 | 山东大学 | Based on metal organic frame administration nano-drug administration system and its preparation method and application |
| CN111467491A (en) * | 2020-04-24 | 2020-07-31 | 东南大学 | Synthesis of platinum modified MOF2-Pt-FA as bidirectional enhanced photodynamic therapy medicine and application of platinum modified MOF2-Pt-FA in tumor therapy |
Non-Patent Citations (4)
| Title |
|---|
| AZADEH GOLMOHAMADPOUR ET AL.: "Antimicrobial photodynamic therapy assessment of three indocyanine green-loaded metal-organic frameworks against Enterococcus faecalis" * |
| YAN ZHANG ET AL.: "Metal‐Organic Framworks supported immunostimulatory oligonucleotides for enhanced immune response and imaging" * |
| ZHIJIN FAN ET AL.: "Reversing cold tumors to hot: An immunoadjuvant-functionalized metalorganic framework for multimodal imaging-guided synergistic photoimmunotherapy" * |
| 李振华等: "基于pH响应及抗原和CpG核酸共载的纳米疫苗运载体系的构建" * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115025248A (en) * | 2021-02-22 | 2022-09-09 | 西安电子科技大学 | Iron-based ICG metal organic nano composite (MONs) and preparation method and application thereof |
| CN115025248B (en) * | 2021-02-22 | 2024-01-23 | 西安电子科技大学 | Iron-based ICG metal organic nano-composite (MONs), preparation method and application thereof |
| CN114259476A (en) * | 2021-12-29 | 2022-04-01 | 中南大学湘雅三医院 | Nanometer preparation for regulating and controlling macrophage, and preparation method and application thereof |
| CN115300641A (en) * | 2022-08-01 | 2022-11-08 | 深圳市人民医院 | Antigen delivery carrier for promoting antigen lysosome escape and activating immune system by targeting dendritic cells and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112007170B (en) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tang et al. | An aza-BODIPY photosensitizer for photoacoustic and photothermal imaging guided dual modal cancer phototherapy | |
| Jia et al. | Synthesis of carbon dots from Hypocrella bambusae for bimodel fluorescence/photoacoustic imaging-guided synergistic photodynamic/photothermal therapy of cancer | |
| CN112007170B (en) | Immune adjuvant functionalized metal organic framework material and preparation method and application thereof | |
| Cui et al. | Amphiphilic chitosan modified upconversion nanoparticles for in vivo photodynamic therapy induced by near-infrared light | |
| Liu et al. | Photosensitizer-conjugated redox-responsive dextran theranostic nanoparticles for near-infrared cancer imaging and photodynamic therapy | |
| KR101035269B1 (en) | Novel photosensitizer based on pholymer derivatives-photosensitizer conjugates for photodynamic therapy | |
| Gao et al. | Ce6/Mn 2+-chelated polydopamine@ black-TiO 2 nanoprobes for enhanced synergistic phototherapy and magnetic resonance imaging in 4T1 breast cancer | |
| Li et al. | MOF@ COF nanocapsule for the enhanced microwave thermal-dynamic therapy and anti-angiogenesis of colorectal cancer | |
| CN108219782B (en) | Near-infrared fluorescent probe, multi-modal nano contrast agent based on probe, preparation and application thereof | |
| CN111529720B (en) | Diagnosis and treatment integrated nano material and preparation method and application thereof | |
| CN107812200B (en) | BSA-gadolinium ionic complex-coated hollow gold nanosheet and preparation method thereof | |
| CN110538151B (en) | Near-infrared light response nano liposome, preparation method thereof and application thereof in tumor cooperative treatment | |
| Zhu et al. | A tumor microenvironment responsive nanotheranostics agent for magnetic resonance imaging and synergistic photodynamic therapy/photothermal therapy of liver cancer | |
| CN112516308B (en) | Near-infrared II-region laser controlled-release drug nano-liposome and preparation method and application thereof | |
| CN109432441A (en) | A kind of preparation method and application for the functional graphene oxide medicinal composition improving tumour infiltration retention effect | |
| CN113230418A (en) | Preparation method and application of iron nanoparticles with ultra-small core-shell structure | |
| CN110755640B (en) | Preparation method and application of gold-platinum composite nano diagnosis and treatment agent | |
| CN114073767A (en) | Targeting response type treatment nanoparticle and preparation method and application thereof | |
| CN109395078B (en) | MoO (MoO)2-ICG multifunctional nano-particles and preparation method and application thereof | |
| Deng et al. | Film-facilitated formation of ferrocenecarboxylic acid-embedded metal-organic framework nanoparticles for sonodynamic osteosarcoma treatment | |
| Yan et al. | Single-laser excitation synergistic photo-and chemodynamic therapy system based on persistent luminescence nanoparticles | |
| Liang et al. | Carbon dots/platinum nanoparticles-loaded mesoporous silica for synergistic photodynamic/catalytic therapy of hypoxic tumors | |
| CN110101876A (en) | Purposes of the novel optoacoustic probe in preparation medicine targeting photoacoustic imaging reagent or drug | |
| CN114601925A (en) | Photosensitive nano material jointly modified by hyaluronic acid and RSL3, preparation method and application thereof | |
| CN115215996B (en) | PDTP-TBZ and application of nano preparation thereof in treating brain glioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |